Spots Global Cancer Trial Database for Screening With Tampons: Evaluating Diagnostic Accuracy and HPV and Assessing Participant Views

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Screening With Tampons: Evaluating Diagnostic Accuracy and HPV and Assessing Participant Views

Official Title: Screening With Tampons: Evaluating Diagnostic Accuracy for STIs, BV and HPV and Assessing Participant Views

Study ID: NCT06154239

Conditions

Chlamydia

Gonorrhea

Bacterial Vaginosis

Human Papilloma Virus

Interventions

DAYE Diagnostic Tampon

Vaginal self-swab

Clinician vaginal swab

Study Description

Brief Summary: Diagnostic trial comparing the diagnostic accuracy of the DAYE Diagnostic Tampon (DDT) with a vaginal swab (self-collected and clinician taken).

Detailed Description: A diagnostic trial comparing the diagnostic accuracy, usability and acceptability of the DAYE Diagnostic Tampon (DDT) compared to standard vaginal self-swabs and clinician administration of a vaginal swabs. Diagnostic accuracy will be compared for detection of Chlamydia, Gonorrhoea, BV \& HPV. A total of 350 eligible participants will be enrolled into the trial in the UK and Italy. To adequately assess DDT performance on specificity and sensitivity, participants will be recruited from one of two groups: * Group 1: 50 participants with a recent confirmed HPV diagnosis (UK and Italy) * Group 2: 300 participants from the general population (UK only) All participants will be randomised according to sample order for the DDT and self-swab using block randomisation: * Group A: Approximately half the participants will perform the self-swab followed by the DDT. * Group B: Approximately half the participants will perform the DDT followed by the self-swab All eligible participants will be provided with a trial kit containing the DDT and self-swab and attend at least 1 clinic visit as part of their participation in the trial. Participants will also provide answers to questionnaires at baseline and after all sampling is complete. Participation in the trial is expected to last approximately 2-3 weeks (dependent on timing of clinic appointment(s)). All samples collected during the trial will be sent to a central laboratory for analysis, either in the UK or Italy i.e., samples will be analysed in the country they were collected.